Condition: Small Cell Lung Carcinoma · Sponsor: Advenchen Laboratories Nanjing Ltd.
This is a multicenter, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of AL8326 tablets in small cell lung cancer (SCLC) patients with disease progression or recurrence after receiving at least second-line treatment regimens.
This description comes directly from the study's public registry record.
yingyin Li · +8657188683590 · anne@advenchen.com.cn
Huaqing He · +8615205140516 · huaqingh@advenchen.com.cn
Always discuss trial participation with your own doctor first.
| JILIN Cancer Hospital | Changchun, Jilin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06247605